Next-Generation Femtech: Urine-Based Cervical Cancer Diagnosis Using a Fluorescent Biothiol Probe with Controlled Smiles Rearrangement

Cervical cancer screening is a crucial field of femtech (female technology). In this work, we disclosed a new femtech solution-a simple, straightforward, and on-site applicable urine-based cervical cancer diagnostic method using a fluorescent biothiol probe. Our newly developed nitrobenzene-based fluorescent probe, named NPS-B, effectively differentiates between cysteine and homocysteine within urine samples via controlled Smiles rearrangement. The analysis of emission-based signals offers the potential utility of this method in cervical cancer. NPS-B was designed by considering the substitution effect and structural polarity of the nitrobenzene-based fluorophore. This controlled modification of nitrobenzene-induced substantial intramolecular charge transfer changes in the fluorophore when exposed to biothiols, resulting in significant changes in photophysical properties. NPS-B displayed different emissions of cysteine and homocysteine in clinical human urine (without prior urine treatment). Overall, our findings provide insights not only into fundamental chemical science but also into the broader domain of applied sciences.